NASDAQ:NBTX Nanobiotix (NBTX) Stock Price, News & Analysis $8.72 +0.02 (+0.29%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Nanobiotix Stock (NASDAQ:NBTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nanobiotix alerts:Sign Up Key Stats Today's Range$8.41▼$8.9150-Day Range$4.73▼$10.0952-Week Range$2.76▼$10.59Volume12,285 shsAverage Volume11,792 shsMarket Capitalization$417.56 millionP/E RatioN/ADividend YieldN/APrice Target$8.00Consensus RatingModerate Buy Company Overview Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma. Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma. The company is actively expanding its global footprint with ongoing trials in the United States, Asia, and other regions. Partnerships and collaborations with academic institutions and pharmaceutical companies support the clinical development and potential commercialization of its lead candidate. In addition to NBTXR3, Nanobiotix continues to explore next-generation nanotherapies and combination strategies aimed at enhancing standard oncology protocols. Founded in 2003 by Dr. Laurent Levy and a team of researchers, Nanobiotix combines expertise in physics, chemistry and oncology to address unmet needs in cancer care. The company maintains R&D facilities in Europe and the United States and is led by Dr. Levy, who serves as Chief Executive Officer. Through its science-driven approach, Nanobiotix seeks to deliver safer, more effective treatment options for patients worldwide and to transform the way radiotherapy is applied in solid tumor oncology.AI Generated. May Contain Errors. Read More Nanobiotix Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks8th Percentile Overall ScoreNBTX MarketRank™: Nanobiotix scored higher than 8% of companies evaluated by MarketBeat, and ranked 901st out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingModerate Buy Consensus RatingNanobiotix has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Downside RiskNanobiotix has a consensus price target of $8.00, representing about 8.3% downside from its current price of $8.73.Amount of Analyst CoverageNanobiotix has received no research coverage in the past 90 days.Read more about Nanobiotix's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nanobiotix are expected to grow in the coming year, from ($1.18) to ($0.86) per share.Read more about Nanobiotix's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.04% of the outstanding shares of Nanobiotix have been sold short.Short Interest Ratio / Days to CoverNanobiotix has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nanobiotix has recently increased by 0.53%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNanobiotix does not currently pay a dividend.Dividend GrowthNanobiotix does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.04% of the outstanding shares of Nanobiotix have been sold short.Short Interest Ratio / Days to CoverNanobiotix has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Nanobiotix has recently increased by 0.53%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Nanobiotix this week, compared to 1 article on an average week.Search Interest2 people have searched for NBTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Nanobiotix insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.45% of the stock of Nanobiotix is held by insiders.Percentage Held by InstitutionsOnly 38.81% of the stock of Nanobiotix is held by institutions.Read more about Nanobiotix's insider trading history. Receive NBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NBTX Stock News HeadlinesNanobiotix to Present at H.C. Wainwright Investment ConferenceSeptember 5 at 5:56 AM | theglobeandmail.comNanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | globenewswire.comCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holding investments longer to using tax-advantaged accounts and strategic loss offsetting, there are ways to reduce your exposure. SmartAsset outlines three capital gains tax strategies for seniors and offers a free tool to connect you with vetted fiduciary financial advisors who can help tailor these tactics to your situation.September 8 at 2:00 AM | SmartAsset (Ad)Guggenheim Reaffirms Their Buy Rating on Nanobiotix (NBTX)July 25, 2025 | theglobeandmail.comNANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3) - MorningstarJuly 8, 2025 | morningstar.comMNANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)July 7, 2025 | globenewswire.comNANOBIOTIX to Participate in the Jefferies Global Healthcare Investor ConferenceMay 28, 2025 | globenewswire.comNanobiotix Provides First Quarter 2025 Operational and Financial UpdateMay 21, 2025 | globenewswire.comSee More Headlines NBTX Stock Analysis - Frequently Asked Questions How have NBTX shares performed this year? Nanobiotix's stock was trading at $2.87 at the start of the year. Since then, NBTX stock has increased by 204.0% and is now trading at $8.7250. When did Nanobiotix IPO? Nanobiotix (NBTX) raised $95 million in an initial public offering on Friday, December 11th 2020. The company issued 6,500,000 shares at $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont served as the underwriters for the IPO. How do I buy shares of Nanobiotix? Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Nanobiotix own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nanobiotix investors own include PayPal (PYPL), Sirius XM (SIRI), Ardelyx (ARDX), BridgeBio Pharma (BBIO), Cogent Communications (CCOI), Citius Pharmaceuticals (CTXR) and Datadog (DDOG). Company Calendar Today9/08/2025Next Earnings (Estimated)9/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NBTX CIK1760854 Webwww.nanobiotix.com Phone33-1-40-26-04-70FaxN/AEmployees100Year FoundedN/APrice Target and Rating Average Price Target for Nanobiotix$8.00 High Price Target$8.00 Low Price Target$8.00 Potential Upside/Downside-8.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.04 Quick Ratio1.04 Sales & Book Value Annual Sales$39.18 million Price / Sales10.66 Cash FlowN/A Price / Cash FlowN/A Book Value($1.51) per share Price / Book-5.77Miscellaneous Outstanding Shares47,940,000Free Float46,289,000Market Cap$417.56 million OptionableNot Optionable Beta0.47 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:NBTX) was last updated on 9/8/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!The $100 billion DeFi prediction nobody's talking about The numbers are staggering: $38.5 billion TVL, $1 m...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredTime is running out on the most obvious trade in historyGold just broke out to fresh all-time highs, silver is up 40% this year, and for the first time in three decad...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nanobiotix S.A. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Nanobiotix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.